A comprehensive review on MEN2B

    1. Steven G Waguespack4
    1. 1Department of Endocrinology, Aix Marseille University, CNRS UM 7286, Assistance Publique Hopitaux de Marseille, Marseille, France
    2. 2Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA
    3. 3Division of Cancer Biology and Genetics, Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada
    4. 4Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    1. Correspondence should be addressed to F Castinetti: frederic.castinetti{at}univ-amu.fr


    MEN2B is a very rare autosomal dominant hereditary tumor syndrome associated with medullary thyroid carcinoma (MTC) in 100% cases, pheochromocytoma in 50% cases and multiple extra-endocrine features, many of which can be quite disabling. Only few data are available in the literature. The aim of this review is to try to give further insights into the natural history of the disease and to point out the missing evidence that would help clinicians optimize the management of such patients. MEN2B is mainly characterized by the early occurrence of MTC, which led the American Thyroid Association to recommend preventive thyroidectomy before the age of 1 year. However, as the majority of mutations are de novo, improved knowledge of the nonendocrine signs would help to lower the age of diagnosis and improve long-term outcomes. Future large-scale studies will be aimed at characterizing more in detail the main characteristics and outcomes of MEN2B.

    • Received 5 July 2017
    • Accepted 10 July 2017
    • Made available online as an Accepted Preprint 1 February 2018
    | Table of Contents